← All Pulse Biosciences, INC filings

Pulse Biosciences, INC 8-K filings

NASDAQ
PLSE
Pulse Biosciences, INC
8-K: Pulse Biosciences Announces Financial Results and $60 Million Rights Offering
Pulse Biosciences reported its 2023 financial results and announced a rights offering to raise up to $60 million.
NASDAQ
PLSE
Pulse Biosciences, INC
8-K: Pulse Biosciences Secures FDA Clearance for CellFX Percutaneous Electrode System
Pulse Biosciences has received FDA 510(k) clearance for its CellFX nsPFA Percutaneous Electrode System, marking a significant milestone for the company's surgical applications.
NASDAQ
PLSE
Pulse Biosciences, INC
8-K: Pulse Biosciences Announces Positive Early Results in Atrial Fibrillation Study
Pulse Biosciences reports favorable 60-day follow-up data from initial patients in its CellFX nsPFA cardiac catheter study, showing promising results for atrial fibrillation treatment.